<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02910102</url>
  </required_header>
  <id_info>
    <org_study_id>RVT-101-2003</org_study_id>
    <nct_id>NCT02910102</nct_id>
  </id_info>
  <brief_title>Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia</brief_title>
  <official_title>A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Axovant Sciences Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Axovant Sciences Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to evaluate the effect of intepirdine (RVT-101) on gait and balance in
      patients with Alzheimer's Disease, Dementia with Lewy Bodies or Parkinson's Disease Dementia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the effect of intepirdine (RVT-101) versus placebo on quantitative and qualitative
      gait and balance parameters.

      Each subject will be randomized 1:1 to one of the following sequences:

      Sequence 1: AB = RVT-101 35 mg during the early treatment period and Placebo during the late
      treatment period

      Sequence 2: BA = Placebo during the early treatment period and RVT-101 35 mg during the late
      treatment period

      Treatment A = RVT-101 35 mg once daily.

      Treatment B = Placebo once daily.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Gait Speed (cm/Sec) Measurements From Baseline to the End of Each Double-blind Treatment Period Based on Computerized Gait Assessment Tools.</measure>
    <time_frame>Baseline, 2 weeks</time_frame>
    <description>Change from baseline in gait speed (cm/sec) measured on an electronic walkway system under single task trial condition (meaning walking only) at the end of each two-week treatment period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Gait Measurements (cm/Sec) Under Dual Task Condition From Baseline to the End of Each Double-blind Treatment Period Based on Computerized Gait Assessment Tools.</measure>
    <time_frame>Baseline, 2 weeks</time_frame>
    <description>Change from baseline in gait speed (cm/sec) measured on an electronic walkway system under dual task trial condition (meaning walking while performing another task) at the end of each two-week treatment period.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Dementia With Lewy Bodies</condition>
  <condition>Parkinson's Disease Dementia</condition>
  <arm_group>
    <arm_group_label>Sequence AB</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>RVT-101 35 mg in Period II and Placebo in Period IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence BA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo in Period II and RVT-101 35 mg in Period IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RVT-101 35 mg</intervention_name>
    <description>RVT-101 once daily, oral, 35-mg tablets</description>
    <arm_group_label>Sequence AB</arm_group_label>
    <arm_group_label>Sequence BA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo once daily, oral</description>
    <arm_group_label>Sequence AB</arm_group_label>
    <arm_group_label>Sequence BA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

        Male or female subject with a clinical diagnosis of Alzheimer's disease (AD), dementia with
        Lewy bodies (DLB), or Parkinson's disease dementia (PDD).

        Mini Mental State Examination score 14 to 26 Gait impairment, as assessed by history
        gathered by the clinical investigator and quantitative measurements Subjects must be on
        stable background acetylcholinesterase inhibitor therapy

        Key Exclusion Criteria:

        History and/or evidence of any other CNS disorder that could be interpreted as a cause of
        dementia (in the opinion of the investigator) Any clinically relevant concomitant disease
        which, in the opinion of the investigator, makes the subject unsuitable for inclusion in
        the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilise Lombardo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Axovant Sciences, Inc., Senior VP Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>US101</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US118</name>
      <address>
        <city>Simi Valley</city>
        <state>California</state>
        <zip>93065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US117</name>
      <address>
        <city>Temecula</city>
        <state>California</state>
        <zip>92591</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US115</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US109</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US116</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33137</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US108</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US106</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US107</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US102</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US111</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>September 16, 2016</study_first_submitted>
  <study_first_submitted_qc>September 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2016</study_first_posted>
  <results_first_submitted>January 15, 2019</results_first_submitted>
  <results_first_submitted_qc>April 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 28, 2020</results_first_posted>
  <last_update_submitted>April 17, 2020</last_update_submitted>
  <last_update_submitted_qc>April 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RVT-101</keyword>
  <keyword>intepirdine</keyword>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Dementia with Lewy bodies</keyword>
  <keyword>Lewy body dementia</keyword>
  <keyword>Parkinson's Disease Dementia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Lewy Body Disease</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 7, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT02910102/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 29, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT02910102/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>68 participants signed consent and were screened for participation. Of these, 40 entered a 2-week single-blind placebo run-in period with treatment with placebo qd. Subjects were allowed to re-screen if they failed the initial screening assessments. All subjects deemed eligible following run-in were randomized to a treatment group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1: AB</title>
          <description>RVT-101 35 mg: once daily, oral, 35-mg tablets in Period II
Placebo in Period IV</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2: BA</title>
          <description>Placebo: once daily, oral, matching tablets in Period II
RVT-101 35 mg: once daily, oral, 35-mg tablets in Period IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent to Treat (ITT) Population</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per-Protocol Population</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population</population>
      <group_list>
        <group group_id="B1">
          <title>Sequence 1: AB</title>
          <description>RVT-101 35 mg: once daily, oral, 35-mg tablets in Period II
Placebo in Period IV</description>
        </group>
        <group group_id="B2">
          <title>Sequence 2: BA</title>
          <description>Placebo: once daily, oral, matching tablets in Period II
RVT-101 35 mg: once daily, oral, 35-mg tablets in Period IV</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.0" lower_limit="68" upper_limit="86"/>
                    <measurement group_id="B2" value="73.8" lower_limit="60" upper_limit="83"/>
                    <measurement group_id="B3" value="75.0" lower_limit="60" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.312" lower_limit="19.23" upper_limit="45.59"/>
                    <measurement group_id="B2" value="25.898" lower_limit="16.01" upper_limit="34.57"/>
                    <measurement group_id="B3" value="26.680" lower_limit="16.01" upper_limit="45.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Gait Speed (cm/Sec) Measurements From Baseline to the End of Each Double-blind Treatment Period Based on Computerized Gait Assessment Tools.</title>
        <description>Change from baseline in gait speed (cm/sec) measured on an electronic walkway system under single task trial condition (meaning walking only) at the end of each two-week treatment period</description>
        <time_frame>Baseline, 2 weeks</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>RVT-101 35 mg</title>
            <description>Subjects who dosed with RVT-101 in both sequences (AB and BA) are included in this analysis</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects who dosed with Placebo in both sequences (AB and BA) are included in this analysis</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Gait Speed (cm/Sec) Measurements From Baseline to the End of Each Double-blind Treatment Period Based on Computerized Gait Assessment Tools.</title>
          <description>Change from baseline in gait speed (cm/sec) measured on an electronic walkway system under single task trial condition (meaning walking only) at the end of each two-week treatment period</description>
          <population>ITT Population</population>
          <units>cm/sec</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="1.845"/>
                    <measurement group_id="O2" value="1.47" spread="1.874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3565</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Each co-primary endpoint was tested at two-sided 5% level of significance, with no adjustments for multiplicity.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.04</ci_lower_limit>
            <ci_upper_limit>2.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Gait Measurements (cm/Sec) Under Dual Task Condition From Baseline to the End of Each Double-blind Treatment Period Based on Computerized Gait Assessment Tools.</title>
        <description>Change from baseline in gait speed (cm/sec) measured on an electronic walkway system under dual task trial condition (meaning walking while performing another task) at the end of each two-week treatment period.</description>
        <time_frame>Baseline, 2 weeks</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>RVT-101 35 mg</title>
            <description>RVT-101 35 mg: once daily, oral
Subjects who dosed with RVT-101 in both sequences (AB and BA) are included in this analysis</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects who dosed with Placebo in both sequences (AB and BA) are included in this analysis</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Gait Measurements (cm/Sec) Under Dual Task Condition From Baseline to the End of Each Double-blind Treatment Period Based on Computerized Gait Assessment Tools.</title>
          <description>Change from baseline in gait speed (cm/sec) measured on an electronic walkway system under dual task trial condition (meaning walking while performing another task) at the end of each two-week treatment period.</description>
          <population>ITT Population</population>
          <units>cm/sec</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" spread="1.517"/>
                    <measurement group_id="O2" value="1.63" spread="1.518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9220</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Each co-primary endpoint was tested at two-sided 5% level of significance, with no adjustments for multiplicity.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.73</ci_lower_limit>
            <ci_upper_limit>3.38</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Screening through post-treatment (Up to 16 Weeks)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>RVT-101 35 mg</title>
          <description>Subjects who dosed with RVT-101 in both sequences (AB and BA) are included</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Subjects who dosed with Placebo in both sequences (AB and BA) are included</description>
        </group>
        <group group_id="E3">
          <title>Screening Period</title>
          <description>Participants screened (0-4 weeks) prior to entering to the first dose of single-blind study medication (ie, prior to the Run-In period)</description>
        </group>
        <group group_id="E4">
          <title>Run-In Period</title>
          <description>Placebo: once daily, oral, pill manufactured to match RVT-101 35 mg tablet (for 2 weeks)</description>
        </group>
        <group group_id="E5">
          <title>RVT-101 Post-Treatment</title>
          <description>Subjects reported adverse events after completing the treatment period. The Post-Treatment period - defined as up to 17 days post-last-dose</description>
        </group>
        <group group_id="E6">
          <title>Placebo Post-Treatment</title>
          <description>Subjects reported adverse events after completing the treatment period. The Post-Treatment period - defined as up to 17 days post-last-dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All proposed manuscripts, publications or abstracts must be reviewed and approved by the Sponsor 60 days prior to submission for publication. All confidential information identified by the Sponsor must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, Clinical Development</name_or_title>
      <organization>Axovant Sciences, Inc.</organization>
      <phone>1-833-296-8268</phone>
      <email>clinicaltrials@axovant.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

